Tonix Pharmaceuticals Holding (TNXP) FY2025 10-K Risk Factors: 16 New, 11 Dropped

What the changes say

Tonix is transitioning from a clinical-stage company to a commercial organization following the August 2025 FDA approval of TONMYA for fibromyalgia.
The company faces heavy reliance on its ability to successfully launch and commercialize TONMYA despite a lack of prior product launch experience.
Operations remain dependent on raising additional capital, securing ongoing government funding, and maintaining compliance with strict regulatory requirements for marketed and pipeline products.

What changed since the prior 10-K

New

NewRISKS RELATED TO OUR BUSINESS
Our prospects are highly dependent on the success of TONMYA. If we are unable to successfully commercialize or maintain approval for TONMYA, our business, financial condition, results of operations and prospects and the value of our common stock will be materially adversely affected
We have never previously launched a product and face significant uncertainty regarding our ability to successfully commercialize TONMYA for fibromyalgia.
NewRISKS RELATED TO OUR BUSINESS
We have a limited operating history and only recently launched TONMYA in the United States, which may make it difficult to evaluate the prospects for our future viability
Our limited operating history and recent commercial launch of TONMYA make it difficult to evaluate our future viability and financial prospects.
NewRISKS RELATED TO OUR BUSINESS
TONMYA and our migraine products remain subject to ongoing regulatory review, and if we fail to comply with continuing regulations, we could lose our approval and the sale of TONMYA or our migraine products could be suspended
TONMYA and our migraine products remain subject to ongoing regulatory review, and non-compliance could result in lost approvals or suspended sales.
NewRISKS RELATED TO OUR BUSINESS
If estimates of the size of the potential market for TONMYA are overstated or data we have used to identify prescribing healthcare providers is inaccurate, our ability to earn revenue to support our business could be materially adversely affected
Our market size estimates and identification of healthcare prescribers for TONMYA may be inaccurate, which could severely limit our revenue.
NewRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products
FDA expedited designations like fast track or priority review do not guarantee faster development, review, or ultimate approval for our product candidates.
NewRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any
Foreign governments outside the United States impose strict price controls and complex reimbursement methodologies that may adversely affect our international revenues.
NewRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
If the FDA approves generic products that compete with TONMYA, sales of TONMYA would be adversely affected
If the FDA approves generic competitors to TONMYA via abbreviated new drug applications, our product sales would be adversely affected.
NewRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
We may never receive regulatory approval to market our current or future product candidates outside of the U.S
We may never receive the necessary regulatory, pricing, and reimbursement approvals to market our products outside of the United States.
NewRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that could materially adversely affect our business
Expanding into foreign markets subjects us to differing regulatory burdens and commercial uncertainties that could harm our business.
NewRISKS RELATED TO OUR INTELLECTUAL PROPERTY RIGHTS AND REGULATORY EXCLUSIVITY
We are dependent on license relationships with third parties for certain of our drug development programs
We depend on third-party license relationships for certain drug development programs and risk losing our rights if we fail to meet obligations.
NewRISKS RELATED TO OUR INTELLECTUAL PROPERTY RIGHTS AND REGULATORY EXCLUSIVITY
We may be unable to protect the confidentiality of our trade secrets, thus harming our business and competitive position
Failure to protect the confidentiality of our trade secrets and unpatented know-how could harm our competitive position.
NewRISKS RELATED TO OUR INTELLECTUAL PROPERTY RIGHTS AND REGULATORY EXCLUSIVITY
Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
We may face costly litigation and claims that our employees have wrongfully used or disclosed trade secrets from former employers.
NewRISKS RELATED TO OUR INTELLECTUAL PROPERTY RIGHTS AND REGULATORY EXCLUSIVITY
We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
NewGENERAL COMPANY-RELATED RISKS
If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market, sell and distribute our products, we may be unable to generate significant product awareness and that lack of awareness may limit the product revenues that we generate
NewGENERAL COMPANY-RELATED RISKS
Changes in tax laws could adversely affect our business and financial condition
NewRISKS RELATED TO OUR STOCK
We may not be able to maintain compliance with the Listing Rules of the NASDAQ Stock Exchange

Dropped

DroppedRISKS RELATED TO OUR BUSINESS
Our prospects are dependent on the continued successful commercialization of Zembrace and Tosymra. To the extent we cannot maintain or increase sales of Zembrace and Tosymra, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline
DroppedRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCILAIZATION
Successful development of our products is uncertain
DroppedRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCILAIZATION
We do not have, and may never obtain, the regulatory approvals we need to market our product candidates
DroppedRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCILAIZATION
If we are required to generate additional data related to safety and efficacy in order to obtain approval for TNX-SL for FM under Section 505(b)(2), we may be unable to meet our anticipated development and commercialization timelines
Reliance on continued successful commercialization of approved drugs Zembrace and Tosymra.
DroppedRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS; COMPETITION
Although we have two approved products on the market, we do not expect revenues from product sales to exceed expenses in the foreseeable future, if at all
DroppedRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS; COMPETITION
Outbreaks of communicable diseases may materially and adversely affect our business, financial condition and results of operations
DroppedGENERAL COMPANY-RELATED RISKS
Our strategy for our marketed products and our product candidates is to control, directly or through contracted third parties, all or most aspects of the product development process, including marketing, sales and distribution
DroppedGENERAL COMPANY-RELATED RISKS
If we are unsuccessful in obtaining a priority review voucher for material threat medical countermeasures, the length of the approval process for our TNX-801 vaccine in development to prevent smallpox and mpox will be longer than the approval process with the priority review voucher
DroppedGENERAL COMPANY-RELATED RISKS
Government entities may take actions that directly or indirectly have the effect of limiting opportunities for our vaccine candidates for COVID-19
DroppedRISKS RELATED TO OUR STOCK
We could be delisted from Nasdaq, which could seriously harm the liquidity of our stock and our ability to raise capital
Inherent risks and uncertainties in the successful development of pharmaceutical products.
DroppedRISKS RELATED TO OUR STOCK
We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline

Reworded

69% rewrittenRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS
We have a history of operating losses and expect to incur losses for the foreseeable future. We may never achieve profitability
Updated to reflect commercial sales of TONMYA starting in Q4 2025 and expanded descriptions of future loss factors.
54% rewrittenRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
Reductions in staffing and funding at FDA and other federal agencies could cause delays in the development and approval of our products
Maintained risk regarding FDA staffing and funding reductions, shifting references slightly.
47% rewrittenRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS
We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance
Removed reference to lacking regulatory approvals and added specific factors contributing to quarterly and annual financial fluctuations.
41% rewrittenGENERAL COMPANY-RELATED RISKS
Developing our TNX-801 vaccine candidate requires testing of challenges with rabbitpox and vaccinia mpox viruses under controlled experimental conditions. The testing of TNX-801 may carry risk of infection and harm to individuals
Removed horsepox virus stock manufacturing references for TNX-1800, focusing solely on the TNX-801 rabbitpox and vaccinia mpox testing risks.
Was: Developing our TNX-1800 and TNX-801 vaccine candidates each require testing of challenges with rabbitpox, vaccinia mpox or SARS-CoV-2 viruses under controlled experimental conditions. The testing of TNX-1800 and TNX-801 may carry risk of infection and harm to individuals
39% rewrittenRISKS RELATED TO OUR BUSINESS
Uncertainty in Government funding and in-kind support policies and programs may adversely affect our business
Updated federal funding risks to note that BARDA has begun withdrawing or terminating some Project NextGen-related awards.
35% rewrittenGENERAL COMPANY-RELATED RISKS
We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth
Added commercialization efforts for TONMYA as a driver for the required expansion of company operations and headcount.
30% rewrittenRISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws
Minor administrative phrasing updates regarding government authorities enforcing healthcare fraud and abuse laws.
29% rewrittenRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS
We will need additional capital to fund our operations. If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations
Extended cash runway projection from Q1 2026 to Q1 2027 and added commercialization of TONMYA as a primary use of cash.
Was: We will need additional capital. If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations
25% rewrittenRISKS RELATED TO OUR BUSINESS
Healthcare legislative or regulatory reform measures, including government restrictions on pricing and reimbursement, may have a negative impact on our business and results of operations

All 68 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS

01We have a history of operating losses and expect to incur losses for the foreseeable future. We may never achieve profitability69% rewritten
02We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance47% rewritten
03Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements
04We will need additional capital to fund our operations. If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations29% rewritten

RISKS RELATED TO OUR BUSINESS

05Our prospects are highly dependent on the success of TONMYA. If we are unable to successfully commercialize or maintain approval for TONMYA, our business, financial condition, results of operations and prospects and the value of our common stock will be materially adversely affectedNew
06We have a limited operating history and only recently launched TONMYA in the United States, which may make it difficult to evaluate the prospects for our future viabilityNew
07TONMYA and our migraine products remain subject to ongoing regulatory review, and if we fail to comply with continuing regulations, we could lose our approval and the sale of TONMYA or our migraine products could be suspendedNew
08If estimates of the size of the potential market for TONMYA are overstated or data we have used to identify prescribing healthcare providers is inaccurate, our ability to earn revenue to support our business could be materially adversely affectedNew
09Coverage and adequate reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably
10Healthcare legislative or regulatory reform measures, including government restrictions on pricing and reimbursement, may have a negative impact on our business and results of operations25% rewritten
11Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market
12Uncertainty in Government funding and in-kind support policies and programs may adversely affect our business39% rewritten

RISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY APPROVAL, MANUFACTURING AND COMMERCIALIZATION

13Our product candidates are novel and still in development
14If preclinical and nonclinical testing or clinical studies for our product candidates are unsuccessful or delayed, we will be unable to meet our anticipated development and commercialization timelines
15We are subject to extensive and costly government regulation
16Our product candidates may cause serious adverse events, or SAEs, or undesirable side effects which may delay or prevent marketing authorization, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales
17Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our productsNew
18Even if approved, our product candidates will be subject to extensive post-approval regulation
19Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws30% rewritten
20If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
21Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if anyNew
22If the FDA approves generic products that compete with TONMYA, sales of TONMYA would be adversely affectedNew
23The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges
24Reductions in staffing and funding at FDA and other federal agencies could cause delays in the development and approval of our products54% rewritten
25We may never receive regulatory approval to market our current or future product candidates outside of the U.SNew
26Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that could materially adversely affect our businessNew
27There may not be market interest in TNX-801
28If technology developed for the purposes of developing new medicines or vaccines can be applied to the creation or development of biological weapons, then our technology may be considered “dual use” technology and be subject to limitations on public disclosure or export
29Competition and technological change may make our product candidates and technologies less attractive or obsolete

RISKS RELATED TO OUR INTELLECTUAL PROPERTY RIGHTS AND REGULATORY EXCLUSIVITY

30If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected
31We are dependent on license relationships with third parties for certain of our drug development programsNew
32We may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming
33If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages, and defend against litigation
34There are risks to our intellectual property based on our international business initiatives
35We may be unable to protect the confidentiality of our trade secrets, thus harming our business and competitive positionNew
36Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secretsNew
37We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable termsNew

GENERAL COMPANY-RELATED RISKS

38We rely on third parties to conduct, supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business
39We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success
40We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth35% rewritten
41Our executive officers and other key personnel are critical to our business, and our future success depends on our ability to retain them
42Any employment agreement we enter into will not ensure the retention of the employee who is a party to the agreement. In addition, we have only limited ability to prevent former employees from competing with us
43If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed
44Failure by our third-party manufacturers to comply with the regulatory guidelines set forth by the FDA with respect to our products and product candidates could delay or prevent the completion of clinical studies, the approval of any product candidates or the commercialization of our products
45We are exposed to cybersecurity and data privacy risks that, if realized, could expose us to legal liability, damage our reputation and harm our business
46Adverse global conditions, including economic uncertainty, may negatively impact our financial results
47Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs
48Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products
49Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete
50Our product candidates may face competition sooner than expected
51If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market, sell and distribute our products, we may be unable to generate significant product awareness and that lack of awareness may limit the product revenues that we generateNew
52We face the risk of product liability claims and may not be able to obtain insurance
53We use hazardous chemicals in our business. Potential claims relating to improper handling, storage or disposal of these chemicals could affect us and be time-consuming and costly
54Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities
55If we retain collaborative partners and our partners do not satisfy their obligations, we will be unable to develop our partnered product candidates
56We face risks in connection with existing and future collaborations with respect to the development, manufacture, and commercialization of our product candidates
57Developing our TNX-801 vaccine candidate requires testing of challenges with rabbitpox and vaccinia mpox viruses under controlled experimental conditions. The testing of TNX-801 may carry risk of infection and harm to individuals41% rewritten
58Changes in tax laws could adversely affect our business and financial conditionNew

RISKS RELATED TO OUR STOCK

59Sales of additional shares of our common stock could cause the price of our common stock to decline
60We may not be able to maintain compliance with the Listing Rules of the NASDAQ Stock ExchangeNew
61An active trading market for our common stock may not be sustained
62The market price of our common stock has been extremely volatile in the past and may be volatile in the future due to numerous circumstances beyond our control
63A “short squeeze” due to a sudden increase in demand for shares of our common stock that largely could lead to extreme price volatility in shares of our common stock
64We do not anticipate paying dividends on our common stock and, accordingly, shareholders must rely on stock appreciation for any return on their investment
65The rights of the holders of common stock may be impaired by the potential issuance of preferred stock
66If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures, or if we discover material weaknesses and deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult
67If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline
68Other companies may have difficulty acquiring us, even if doing so would benefit our stockholders, due to provisions under our corporate charter and bylaws, as well as Nevada law

Other Tonix Pharmaceuticals Holding 10-Ks

FY2024 10-K risk factors
63 risks
Cash runway extends only into the first quarter of 2026, creating a going concern risk.
Filed Mar 18, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.